BIT Capital GmbH Increases Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

BIT Capital GmbH boosted its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 239.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 285,954 shares of the company’s stock after acquiring an additional 201,808 shares during the period. BIT Capital GmbH owned 0.36% of Viridian Therapeutics worth $5,482,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Great Point Partners LLC boosted its stake in shares of Viridian Therapeutics by 50.0% during the 3rd quarter. Great Point Partners LLC now owns 750,000 shares of the company’s stock valued at $17,062,000 after purchasing an additional 250,000 shares in the last quarter. Lord Abbett & CO. LLC bought a new stake in Viridian Therapeutics during the 3rd quarter valued at approximately $8,917,000. JPMorgan Chase & Co. grew its holdings in shares of Viridian Therapeutics by 218.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 400,351 shares of the company’s stock worth $9,108,000 after acquiring an additional 274,641 shares during the period. Barclays PLC raised its position in shares of Viridian Therapeutics by 113.1% in the 3rd quarter. Barclays PLC now owns 125,397 shares of the company’s stock worth $2,851,000 after acquiring an additional 66,550 shares in the last quarter. Finally, Point72 Asset Management L.P. purchased a new position in shares of Viridian Therapeutics in the 3rd quarter valued at approximately $788,000.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. Wells Fargo & Company reaffirmed an “equal weight” rating and issued a $27.00 price target (down from $37.00) on shares of Viridian Therapeutics in a research note on Thursday, December 19th. Royal Bank of Canada upped their target price on shares of Viridian Therapeutics from $44.00 to $47.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 17th. Needham & Company LLC reissued a “buy” rating and set a $38.00 price target on shares of Viridian Therapeutics in a research report on Tuesday, January 7th. Finally, HC Wainwright reissued a “buy” rating and set a $34.00 price objective on shares of Viridian Therapeutics in a research note on Monday, December 16th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, Viridian Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $35.70.

Viridian Therapeutics Stock Down 4.3 %

VRDN stock opened at $14.16 on Thursday. The stock has a market capitalization of $1.15 billion, a P/E ratio of -3.29 and a beta of 1.05. The company has a debt-to-equity ratio of 0.04, a current ratio of 18.55 and a quick ratio of 18.55. Viridian Therapeutics, Inc. has a 1-year low of $11.40 and a 1-year high of $27.20. The business has a fifty day moving average price of $16.87 and a 200-day moving average price of $19.73.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($1.05) by $0.24. The company had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.05 million. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. Equities analysts forecast that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current fiscal year.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.